Latest news with #H5
Canada Standard
7 hours ago
- Health
- Canada Standard
Update on the Canadian Food Inspection Agency's actions at an HPAI infected premise at a British Columbia ostrich farm
The Canadian Food Inspection Agency (CFIA) and Canada's national poultry sectors have been responding to detections of highly pathogenic avian influenza (HPAI) in Canada since December 2021. Industry has been highly supportive of the CFIA in its response to HPAI, working collaboratively to implement control measures and protect animal health. The CFIA has acted to minimize the risk of the virus spreading within Canadian flocks and to other animals. All avian influenza viruses, particularly H5 and H7 viruses, have the potential to infect mammals, including humans. Our disease response aims to protect public and animal health, minimize impacts on the domestic poultry industry, and the Canadian economy. The CFIA's response to highly pathogenic avian influenza in domestic poultry is based on an approach known as "stamping-out", as defined by the World Organisation for Animal Health (WOAH) Terrestrial Animal Health Code. Stamping-out is the internationally recognized standard and is a primary tool to manage the spread of HPAI and mitigate risks to animal and human health as well as enable international trade. It includes steps to eliminate the virus from an infected premises, including the humane depopulation and disposal of infected animals, and disinfection of premises. There are ongoing risks to animal and human health and Canada's export market access Allowing a domestic poultry flock known to be exposed to HPAI to remain alive means a potential source of the virus persists. It increases the risk of reassortment or mutation of the virus, particularly with birds raised in open pasture where there is ongoing exposure to wildlife. CFIA's National Centre for Foreign Animal Disease (NCFAD) identified that the current HPAI infection in these ostriches is a novel reassortment not seen elsewhere in Canada. This assortment includes the D1.3 genotype, which has been associated with a human infection in a poultry worker in Ohio. A human case of H5N1 in BC earlier this year required critical care, and an extended hospital stay for the patient, and there have been a number of human cases in the United States, including a fatality. Stamping-out and primary control zones enable international trade as it allows Canada to contain outbreaks within a specific area, meet the requirements of zoning arrangements with trading partners, and permit Canada's poultry industry to export from disease-free regions. Continued export market access supports Canadian families and poultry farmers whose livelihoods depend on maintaining international market access for $1.75 billion in exports. Current status of the infected premise at Universal Ostrich Farm Universal Ostrich Farm has not cooperated with the requirements set out under the Health of Animals Act including failure to report the initial cases of illness and deaths to the CFIA and failure to adhere to quarantine orders. Universal Ostrich Farm was issued two notices of violations with penalty, totaling $20,000. The farm also failed to undertake appropriate biosecurity risk mitigation measures such as limiting wild bird access to the ostriches, controlling water flow from the quarantine zone to other parts of the farm, or improving fencing. These actions significantly increase the risk of disease transmission and reflect a disregard for regulatory compliance and animal health standards. Universal Ostrich Farm has not substantiated their claims of scientific research. CFIA has not received any evidence of scientific research being done at the infected premises. Research documentation was not provided during the review of their request for exemption from the disposal order based on unique genetics or during the judicial review process. Further, the current physical facilities at their location are not suitable for controlled research activities or trials. On May 13, 2025, the Federal court dismissed both of Universal Ostrich Farm's applications for judicial review. The interlocutory injunction pausing the implementation of the disposal order was also vacated. Following the May 13 court ruling, the farm owners and supporters have been at the farm in an apparent attempt to prevent the CFIA from carrying out its operations at the infected premises. This has delayed a timely and appropriate response to the HPAI infected premises, resulting in ongoing health risks to animals and humans. CFIA's next steps at the infected premises Given that the flock has had multiple laboratory-confirmed cases of H5N1 and the ongoing serious risks for animal and human health, and trade, the CFIA continues planning for humane depopulation with veterinary oversight at the infected premises. The CFIA takes the responsibility to protect the health of animals and Canadians extremely seriously as we conduct these necessary disease control measures to protect public health and minimize the economic impact on Canada's poultry industry. For more detailed information on the CFIA's continued response to HPAI at this infected premises, please visit our website.
Cision Canada
12 hours ago
- Health
- Cision Canada
Update on the Canadian Food Inspection Agency's actions at an HPAI infected premise at a British Columbia ostrich farm Français
OTTAWA, ON, May 30, 2025 /CNW/ - The Canadian Food Inspection Agency (CFIA) and Canada's national poultry sectors have been responding to detections of highly pathogenic avian influenza (HPAI) in Canada since December 2021. Industry has been highly supportive of the CFIA in its response to HPAI, working collaboratively to implement control measures and protect animal health. The CFIA has acted to minimize the risk of the virus spreading within Canadian flocks and to other animals. All avian influenza viruses, particularly H5 and H7 viruses, have the potential to infect mammals, including humans. Our disease response aims to protect public and animal health, minimize impacts on the domestic poultry industry, and the Canadian economy. The CFIA's response to highly pathogenic avian influenza in domestic poultry is based on an approach known as "stamping-out", as defined by the World Organisation for Animal Health (WOAH) Terrestrial Animal Health Code. Stamping-out is the internationally recognized standard and is a primary tool to manage the spread of HPAI and mitigate risks to animal and human health as well as enable international trade. It includes steps to eliminate the virus from an infected premises, including the humane depopulation and disposal of infected animals, and disinfection of premises. There are ongoing risks to animal and human health and Canada's export market access Allowing a domestic poultry flock known to be exposed to HPAI to remain alive means a potential source of the virus persists. It increases the risk of reassortment or mutation of the virus, particularly with birds raised in open pasture where there is ongoing exposure to wildlife. CFIA's National Centre for Foreign Animal Disease (NCFAD) identified that the current HPAI infection in these ostriches is a novel reassortment not seen elsewhere in Canada. This assortment includes the D1.3 genotype, which has been associated with a human infection in a poultry worker in Ohio. A human case of H5N1 in BC earlier this year required critical care, and an extended hospital stay for the patient, and there have been a number of human cases in the United States, including a fatality. Stamping-out and primary control zones enable international trade as it allows Canada to contain outbreaks within a specific area, meet the requirements of zoning arrangements with trading partners, and permit Canada's poultry industry to export from disease-free regions. Continued export market access supports Canadian families and poultry farmers whose livelihoods depend on maintaining international market access for $1.75 billion in exports. Current status of the infected premise at Universal Ostrich Farm Universal Ostrich Farm has not cooperated with the requirements set out under the Health of Animals Act including failure to report the initial cases of illness and deaths to the CFIA and failure to adhere to quarantine orders. Universal Ostrich Farm was issued two notices of violations with penalty, totaling $20,000. The farm also failed to undertake appropriate biosecurity risk mitigation measures such as limiting wild bird access to the ostriches, controlling water flow from the quarantine zone to other parts of the farm, or improving fencing. These actions significantly increase the risk of disease transmission and reflect a disregard for regulatory compliance and animal health standards. Universal Ostrich Farm has not substantiated their claims of scientific research. CFIA has not received any evidence of scientific research being done at the infected premises. Research documentation was not provided during the review of their request for exemption from the disposal order based on unique genetics or during the judicial review process. Further, the current physical facilities at their location are not suitable for controlled research activities or trials. On May 13, 2025, the Federal court dismissed both of Universal Ostrich Farm's applications for judicial review. The interlocutory injunction pausing the implementation of the disposal order was also vacated. Following the May 13 court ruling, the farm owners and supporters have been at the farm in an apparent attempt to prevent the CFIA from carrying out its operations at the infected premises. This has delayed a timely and appropriate response to the HPAI infected premises, resulting in ongoing health risks to animals and humans. CFIA's next steps at the infected premises Given that the flock has had multiple laboratory-confirmed cases of H5N1 and the ongoing serious risks for animal and human health, and trade, the CFIA continues planning for humane depopulation with veterinary oversight at the infected premises. The CFIA takes the responsibility to protect the health of animals and Canadians extremely seriously as we conduct these necessary disease control measures to protect public health and minimize the economic impact on Canada's poultry industry. For more detailed information on the CFIA's continued response to HPAI at this infected premises, please visit our website. The Canadian Food Inspection Agency (CFIA) touches the lives of all Canadians in so many positive ways. Each day, hard-working CFIA employees–including inspectors, veterinarians and scientists–inspect food for safety risks, protect plants from pests and invasive species, and respond to animal diseases that could threaten Canada's national herd and human health. Guided by science-based decision-making and modern regulations, the Agency works tirelessly to ensure access to safe and healthy food in Canada, and support access to international markets for our high-quality agricultural products. To learn more, visit
Yahoo
12 hours ago
- Business
- Yahoo
Update on the Canadian Food Inspection Agency's actions at an HPAI infected premise at a British Columbia ostrich farm
OTTAWA, ON, May 30, 2025 /CNW/ - The Canadian Food Inspection Agency (CFIA) and Canada's national poultry sectors have been responding to detections of highly pathogenic avian influenza (HPAI) in Canada since December 2021. Industry has been highly supportive of the CFIA in its response to HPAI, working collaboratively to implement control measures and protect animal health. The CFIA has acted to minimize the risk of the virus spreading within Canadian flocks and to other animals. All avian influenza viruses, particularly H5 and H7 viruses, have the potential to infect mammals, including humans. Our disease response aims to protect public and animal health, minimize impacts on the domestic poultry industry, and the Canadian economy. The CFIA's response to highly pathogenic avian influenza in domestic poultry is based on an approach known as "stamping-out", as defined by the World Organisation for Animal Health (WOAH) Terrestrial Animal Health Code. Stamping-out is the internationally recognized standard and is a primary tool to manage the spread of HPAI and mitigate risks to animal and human health as well as enable international trade. It includes steps to eliminate the virus from an infected premises, including the humane depopulation and disposal of infected animals, and disinfection of premises. There are ongoing risks to animal and human health and Canada's export market access Allowing a domestic poultry flock known to be exposed to HPAI to remain alive means a potential source of the virus persists. It increases the risk of reassortment or mutation of the virus, particularly with birds raised in open pasture where there is ongoing exposure to wildlife. CFIA's National Centre for Foreign Animal Disease (NCFAD) identified that the current HPAI infection in these ostriches is a novel reassortment not seen elsewhere in Canada. This assortment includes the D1.3 genotype, which has been associated with a human infection in a poultry worker in Ohio. A human case of H5N1 in BC earlier this year required critical care, and an extended hospital stay for the patient, and there have been a number of human cases in the United States, including a fatality. Stamping-out and primary control zones enable international trade as it allows Canada to contain outbreaks within a specific area, meet the requirements of zoning arrangements with trading partners, and permit Canada's poultry industry to export from disease-free regions. Continued export market access supports Canadian families and poultry farmers whose livelihoods depend on maintaining international market access for $1.75 billion in exports. Current status of the infected premise at Universal Ostrich Farm Universal Ostrich Farm has not cooperated with the requirements set out under the Health of Animals Act including failure to report the initial cases of illness and deaths to the CFIA and failure to adhere to quarantine orders. Universal Ostrich Farm was issued two notices of violations with penalty, totaling $20,000. The farm also failed to undertake appropriate biosecurity risk mitigation measures such as limiting wild bird access to the ostriches, controlling water flow from the quarantine zone to other parts of the farm, or improving fencing. These actions significantly increase the risk of disease transmission and reflect a disregard for regulatory compliance and animal health standards. Universal Ostrich Farm has not substantiated their claims of scientific research. CFIA has not received any evidence of scientific research being done at the infected premises. Research documentation was not provided during the review of their request for exemption from the disposal order based on unique genetics or during the judicial review process. Further, the current physical facilities at their location are not suitable for controlled research activities or trials. On May 13, 2025, the Federal court dismissed both of Universal Ostrich Farm's applications for judicial review. The interlocutory injunction pausing the implementation of the disposal order was also vacated. Following the May 13 court ruling, the farm owners and supporters have been at the farm in an apparent attempt to prevent the CFIA from carrying out its operations at the infected premises. This has delayed a timely and appropriate response to the HPAI infected premises, resulting in ongoing health risks to animals and humans. CFIA's next steps at the infected premises Given that the flock has had multiple laboratory-confirmed cases of H5N1 and the ongoing serious risks for animal and human health, and trade, the CFIA continues planning for humane depopulation with veterinary oversight at the infected premises. The CFIA takes the responsibility to protect the health of animals and Canadians extremely seriously as we conduct these necessary disease control measures to protect public health and minimize the economic impact on Canada's poultry industry. For more detailed information on the CFIA's continued response to HPAI at this infected premises, please visit our website. The Canadian Food Inspection Agency (CFIA) touches the lives of all Canadians in so many positive ways. Each day, hard-working CFIA employees–including inspectors, veterinarians and scientists–inspect food for safety risks, protect plants from pests and invasive species, and respond to animal diseases that could threaten Canada's national herd and human health. Guided by science-based decision-making and modern regulations, the Agency works tirelessly to ensure access to safe and healthy food in Canada, and support access to international markets for our high-quality agricultural products. To learn more, visit SOURCE Canadian Food Inspection Agency (CFIA) View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
Pfizer CEO: HHS claims of ‘concealed safety concerns' on mRNA vaccines are ‘completely inaccurate'
Pharmaceutical rivals don't often come to each other's defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird flu vaccine, claiming that 'mRNA technology remains under-tested,' Pfizer's chief executive is speaking up. 'MRNA probably is the most utilized vaccine in the history of humanity,' Pfizer CEO Dr. Albert Bourla said Friday, noting that there have been about 1.5 billion mRNA vaccine doses against Covid-19 administered worldwide from his company alone – not counting those from Moderna. 'So it is extremely well-tested.' HHS said Wednesday that it was canceling at least $590 million in federal funding the previous administration had granted for Moderna to use its mRNA technology to develop pandemic influenza vaccines, including those against H5 avian flu viruses. The H5N1 strain has infected at least 70 people and killed one in the US since last year. 'We concluded that continued investment in Moderna's H5N1 mRNA vaccine was not scientifically or ethically justifiable,' an HHS spokesperson said, claiming, 'the reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.' Asked his response to those comments, Bourla responded, 'both of them are completely inaccurate.' The pharma giant's chief spoke with CNN on Friday as Pfizer presented new data on a colorectal cancer drug at the American Society of Clinical Oncology, or ASCO, conference in Chicago, the world's largest meeting on cancer research. Pfizer's drug, Braftovi, was shown to double the length of time patients with an aggressive form of colorectal cancer lived with treatment: an average of 30 months compared with 15 in a clinical trial. It's a 'very, very important finding,' Bourla said, noting that colorectal cancer rates, 'particularly among younger people, are skyrocketing right now.' And while Pfizer is making big bets on cancer research, its CEO said he's not taking his foot off the pedal with investment in vaccines either, despite a 'very big gap' between the company and HHS – particularly Secretary Robert F. Kennedy Jr. – on their approaches to the subject. 'The science is proven,' Bourla said. 'The things they will do that will reduce, maybe, vaccination rates will come back and bite us.' Diseases will return, he said, and 'that will not take a long time.' Already, the US is experiencing one of its largest measles outbreaks since the disease was declared eliminated in this country in 2000, and rates of whooping cough, or pertussis, have increased as well. The recurrence of disease probably 'means that immediately they will have to reverse it,' Bourla said, suggesting that there will be public health efforts to increase vaccination rates in response, and 'they will go back to what every country in the world is doing.' Bourla worked with the first Trump administration to advance the company's Covid-19 vaccine through Operation Warp Speed in 2020, although he noted that Pfizer didn't accept federal funding to support vaccine development, only for the purchase of vaccines after the fact. He said that despite the gap on vaccines, 'when you speak with them, including Secretary Kennedy, I have found several topics that we are in, surprisingly, alignment.' Taking on cancer is one key area of agreement, according to the company. Bourla cited executive orders from President Donald Trump encompassing issues like addressing shorter market exclusivity for pills compared with injectable medicines under the Inflation Reduction Act – something the industry calls the 'pill penalty' – drug discounts to hospitals in a program known as 340B, and ratcheting up scrutiny on pharmacy benefit managers' role in drug pricing. 'We are working to address those things as we agree to disagree on the things that divide us,' Bourla said. He noted that he is against the administration's proposed 40% budget cut for the National Institutes of Health, emphasizing that the US is 'the dominant scientific force in biomedical sciences right now, and it is because we have created this ecosystem,' in which NIH funding supports academic research that can lead to new discoveries picked up by the pharmaceutical industry and made into medicines. 'If we break any link of this chain of this large ecosystem,' Bourla said, 'that's not good for us, and actually, it's a gift to our friends in China.' Bourla also took issue with HHS's actions on Covid-19 vaccines in the past two weeks: saying that the US Food and Drug Administration will change the way it approves updated shots for people who aren't in vulnerable groups and that the US Centers for Disease Control and Prevention will no longer recommend Covid-19 vaccines to healthy children and pregnant women. In previous years, Covid-19 vaccines had been updated in a similar way to seasonal flu shots, based on evidence that they generate an immune response; clinical trials that are required to show a vaccine's effect in preventing cases of disease are thought to take too long, potentially, to be feasible every season. What's more, the FDA and its advisers had previously deemed the vaccine updates small enough to not change their safety profile. Asked whether Pfizer would be able to run clinical trials quickly enough to make updated vaccines available to everyone, not just those in vulnerable groups, Bourla said, 'You are raising some very real concerns that we have.' Bourla noted that the implications of the Trump administration's changes to US health agency policies aren't entirely clear. But 'the issue is that that is not based on any scientific data. It's just based on a belief.' 'The appropriate process has not been followed; this is not just: the secretary or someone at a high level issues, let's say, a new rule,' he said. 'You need to follow a process which is reviews, experts, professional staff of FDA and all of that.' Dorit Reiss, a professor of law at UC Law San Francisco, suggested that HHS's 'bad administrative procedure' in announcing the updated CDC recommendations 'will be an issue' if they're challenged in court. Would Pfizer consider filing a lawsuit? 'My initial reaction is that I would prefer to find solutions but not create tensions,' Bourla replied. 'But of course, if we feel that we have to, we will.' Overall, the CEO emphasized that he has found the administration willing to engage in discussions, noting that 'we maintain a very, very close relationship' with the White House. 'I can't complain they don't listen to us,' Bourla said.
Yahoo
a day ago
- General
- Yahoo
RFK Jr. has named himself the official arbiter of science
Just two weeks ago, Health and Human Services Secretary Robert F. Kennedy Jr. told Congress that his 'opinions about vaccines are irrelevant' and that nobody should 'take advice' from him about getting them. How quickly things change. In one decision after another, the Trump administration's recent actions have shown that Kennedy, with his poor understanding of basic medicine, has deemed himself the final arbiter of vaccine science in the U.S. On Wednesday, Moderna announced that HHS canceled a $766 million contract with the company to develop potential pandemic influenza strains, including H5N1 bird flu. In the same statement, Moderna also announced that the new vaccine it had been developing against H5 influenza strains, mRNA-1018, had positive results after being tested in 300 adults. As its name indicates, this developmental vaccine used messenger RNA, the same method that was used to develop the Covid-19 vaccine. Earlier this month, Kennedy announced that all new vaccines would need to be developed without using mRNA technology, despite its proven efficacy and safety. He has also demanded that new Covid boosters undergo more rigorous trials than previously required — including full placebo studies — to gain approval for the market. The decision follows last week's announcement from the Food and Drug Administration that annual Covid boosters will be limited moving forward to people 65 and older and/or who have a high risk of severe Covid. According to the FDA, the eligible conditions for the latter range from asthma to pregnancy to diabetes and 'physical inactivity.' The FDA estimates that '100 million to 200 million Americans will have access to vaccines in this manner,' which calls into question the need to limit them at all. In a commentary in the New England Journal of Medicine, FDA Commissioner Marty Makary and vaccine chief Vinay Prasad cited the hesitancy of Americans to get the booster as a reason for pulling back who can access it. In a moment of extreme irony, the pair also blamed the booster program for declining vaccination rates more broadly: There may even be a ripple effect: public trust in vaccination in general has declined, resulting in a reluctance to vaccinate that is affecting even vital immunization programs such as that for measles–mumps–rubella (MMR) vaccination, which has been clearly established as safe and highly effective. In recent years, reduced MMR vaccination rates have been a growing concern and have contributed to serious illness and deaths from measles. It is duplicitous at best to say more study is needed to reassure the public when the science isn't what's in question here. A more apt culprit would most likely be their boss, as Kennedy has been at the forefront of the movement to paint vaccines as unsafe. The anti-vax campaign has helped measles go from a disease of the past to a current concern as outbreaks pop up around the country. Kennedy went even further Tuesday with a surprise announcement that the Centers for Disease Control and Prevention would no longer recommend including the Covid vaccine in its immunization schedule for 'healthy children and healthy pregnant women.' According to The Washington Post, the CDC itself was unaware that this change would be coming before Kennedy posted about it on X. Moreover, the video Kennedy posted, the guidance given internally to CDC staffers and the FDA's commentary last week all contradict one another about exactly who still qualifies for a Covid booster. Kennedy's influence over what the scientists under him can say could strengthen even further in coming days. Earlier this week, he threatened to stop government researchers at the National Institutes of Health and other agencies from publishing their findings in major medical journals like the NEMJ and The Lancet. 'Unless those journals change dramatically, we are going to stop NIH scientists from publishing in them, and we're going to create our own journals in-house,' Kennedy warned in a podcast appearance. It is the antithesis of science that predetermined outcomes be substituted for observation and analysis. It would likewise be naive to suggest that there has never been any sort of political influence on how science is practiced. But Kennedy's blatant positioning of himself as the ultimate judge of how to keep Americans healthy goes beyond the pale. He may say nobody should 'take advice' from him about vaccination — but he's not offering advice anymore. He's telling America how things are going to be from now on. This article was originally published on
